Completed PHASE1 INTERVENTIONAL 3-arm NCT01762839

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers

Sponsor: Melinta Therapeutics, Inc.

Conditions Healthy

Interventions Moxifloxacin Placebo Single-Dose IV Oritavancin Diphosphate

Updated 7 times since 2017 Last updated: Jan 30, 2024 Started: Dec 27, 2012 Primary completion: Jan 31, 2013 Completion: Feb 11, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Melinta Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Melinta Therapeutics, Inc.

Data source: Melinta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• West Bend, United States